The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

類似資料

• Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
  著者:: Martini A, 等
  出版事項: (2011-09-01)
• Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
  著者:: Caorsi, R, 等
  出版事項: (2011)
• National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
  著者:: Bibalo, C, 等
  出版事項: (2011)
• Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1β secretion
  著者:: Tassi, Sara, 等
  出版事項: (2010)
• Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases
  著者:: Papa, Riccardo, 等
  出版事項: (2020)